INNOVENT BIO (01801.HK)'s total product revenue for 2024 amounted to more than RMB8.2 billion, representing a robust YoY ...

The potential of monoclonal antibodies (mAbs) as therapies is indisputable. The current mAbs market is expected to be around ~USD 150 billion. In 2021, five out of the top 10 selling drugs were ...

Certain antiviral and mAb therapies were shown to lower mortality and hospitalization rates in those infected with SARS-CoV-2 Omicron variants.

Mirikizumab showed superior maintenance efficacy over most treatments for ulcerative colitis (UC), according to a network ...

We recently published a list of 10 Best Annual Dividend Stocks To Buy Now. In this article, we are going to take a look at where Roche Holding AG (OTC:RHHBY) stands against other best annual dividend ...

Ubrelvy and Nurtec are prescription medications taken to treat migraines. Though they share similarities, Ubrelvy is for acute treatment, while Nurtec can be taken for immediate symptom relief.

as they pile up in the list of approved biologics in 2009. Cormac Sheridan reports. Last year was a vintage year for the bio-pharmaceutical industry in two respects. Four monoclonal antibodies ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

Omeros Corporation today announced two presentations that will be featured at the 2025 Tandem Meetings ? the Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and ...

The French drugmaker is paying $17.5 million upfront to kick off the collaboration, which will see Adagene's SAFEbody technology applied to monoclonal and bispecific antibodies for a range of ...

Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded.